Pulmonary alveolar proteinosis

Last updated
Pulmonary alveolar proteinosis
Other namesalveolar proteinosis
Pulmonary alveolar proteinosis -3- high mag.jpg
Micrograph of pulmonary alveolar proteinosis, showing the characteristic airspace filling with focally dense globs referred to as chatter or dense bodies. H&E stain.
Specialty Pulmonology   OOjs UI icon edit-ltr-progressive.svg

Pulmonary alveolar proteinosis (PAP) is a rare lung disorder characterized by an abnormal accumulation of surfactant-derived lipoprotein compounds within the alveoli of the lung. The accumulated substances interfere with the normal gas exchange and expansion of the lungs, ultimately leading to difficulty breathing and a predisposition to developing lung infections. The causes of PAP may be grouped into primary (autoimmune PAP, hereditary PAP), secondary (multiple diseases), and congenital (multiple diseases, usually genetic) causes, although the most common cause is a primary autoimmune condition in an individual.

Contents

Signs and symptoms

The signs and symptoms of PAP include shortness of breath, [1] cough, low grade fever, and weight loss. Additionally, the clinical course of PAP is unpredictable. Spontaneous remission is recognized, and some patients have stable symptoms. Death may occur due to the progression of PAP or of any underlying associated disease. Individuals with PAP are more vulnerable to lung infections such as nocardiosis, Mycobacterium avium-intracellulare infection, or fungal infections. [1]

Causes

The abnormal accumulation of lipoproteinaceous compounds in PAP is due to impaired surfactant regulation and clearance. This is usually related to impaired alveolar macrophage function. [2] In adults, the most common cause of PAP is an autoimmunity to granulocyte-macrophage colony stimulating factor (GM-CSF), a critical factor in development of alveolar macrophages. Decreased bioavailability of GM-CSF results in poor alveolar macrophages development and function, which results in accumulation of surfactant and related products. [2]

Secondary causes of PAP are those in which the accumulation of lipoproteinaceous compounds is secondary to another disease process. This has been recognized in the settings of certain cancers (such as myeloid leukemia), lung infections, or environmental exposure to dusts or chemicals, such as nickel. [3]

Although the cause of PAP was not originally understood, a major breakthrough in the understanding of the cause of the disease came by the chance observation that mice bred for experimental study to lack a hematologic growth factor known as granulocyte-macrophage colony stimulating factor (GM-CSF) developed a pulmonary syndrome of abnormal surfactant accumulation resembling human PAP. [4]

The implications of this finding are still being explored, but significant progress was reported in February 2007. Researchers in that report discussed the presence of anti-GM-CSF autoantibodies in patients with PAP, and duplicated that syndrome with the infusion of these autoantibodies into mice. [5]

Familial or sporadic inactivating mutations in one of the two parental GATA2 genes produces an autosomal dominant disorder termed GATA2 deficiency. The GATA2 gene produces the GATA2 transcription factor which is critical for the embryonic development, maintenance, and functionality of blood-forming, lympathic-forming, and other tissue-forming cells. Individuals with a single GATA2 inactivating mutation present with a wide range of disorders including pulmonary alveolar proteinosis. GATA2 mutation-based pulmonary alveolar proteinosis is associated with normal levels of GM-CSF and commonly improves or is avoided in afflicted individuals who successfully receive a hematopoietic stem cell transplantation. [6] [7]

Genetics

Hereditary pulmonary alveolar proteinosis is a recessive genetic condition in which individuals are born with genetic mutations that deteriorate the function of the CSF2 receptor alpha on alveolar macrophages. Consequently, a messenger molecule known as granulocyte/macrophage-colony stimulating factor (GM-CSF) is unable to stimulate alveolar macrophages to clear surfactant, leading to difficulty with breathing. The gene for the CSF2 receptor alpha is located in the 5q31 region of chromosome 5, and the gene product can also be referred to as granulocyte macrophage colony-stimulating factor receptor. [8] [9]

Diagnosis

Intermediate magnification micrograph of pulmonary alveolar proteinosis. H&E stain. Pulmonary alveolar proteinosis -3- intermed mag.jpg
Intermediate magnification micrograph of pulmonary alveolar proteinosis. H&E stain.

The diagnosis of PAP is made using a combination of a person's symptoms, chest imaging, and microscopic evaluation of lung washing/tissue. Additional testing for serum anti-GM-CSF antibodies are helpful for confirmation. [10]

Although both the symptoms and imaging findings are stereotypical and well-described, they are non-specific and indistinguishable from many other conditions. For example, chest x-ray may show alveolar opacities, and a CT may show a crazy paving lung pattern, both of which are seen more commonly in numerous other conditions. [11] Thus, the diagnosis primarily depends on the pathology findings.[ citation needed ]

Lung washings or tissue for histopathologic analysis are most commonly obtained using bronchoalveolar lavage and/or lung biopsy. [12] Characteristic biopsy findings show filling of the alveoli (and sometimes terminal bronchioles) with an amorphous eosinophilic material, which stains strongly positive on PAS stain and the PAS diastase stain. The surrounding alveoli and pulmonary interstitium remain relatively normal. [13] Electron microscopy of the sample, although not typically performed due to impracticality, shows lamellated bodies representing surfactant. [14] An alternative diagnosis with similar histomorphologic findings is Pneumocystis jirovicii pneumonia. [14]

Lung washings characteristically yield a fluid which is "milky"composition. Under the microscope, samples show 20-50 micrometer PAS-positive globules on a background of finely granular or amorphous PAS-positive material. There is typically a low numbers of macrophages and inflammatory cells (although this is variable). [13] [14]

Treatment

The standard treatment for PAP is whole-lung lavage [15] [16] [17] and supportive care. [18] [19] [20] Whole lung lavage is a procedure performed under general anesthesia, in which one lung is pumped with oxygen (ventilated lung), and the other lung (non-ventilated lung) is filled with a warm saline solution (up to 20 L) and drained, removing any proteinaceous effluent along with it. [21] This is generally effective at improving PAP symptoms, often for a prolonged period of time. Other treatments still being studied include subcutaneous and inhaled GM-CSF, and rituximab, an intravenous infusion that works to stop the production of the autoantibodies responsible for autoimmune PAP. [18] [19] [20] [22] Lung transplantation has been performed in individuals with the various forms of PAP; however, this is often only used when all other treatment options have failed and significant lung damage has developed due to the risks, complications, or recurrence of PAP following transplantation. [20] [22] [23] As of 2022, methionine oral supplementation has been tested on patients with methionine tRNA synthetase-related PAP and has strong evidence of its efficacy on these patients. [24]

Epidemiology

The disease is more common in males and in tobacco smokers.[ citation needed ]

In a recent epidemiologic study from Japan, [25] Autoimmune PAP has an incidence and prevalence higher than previously reported and is not strongly linked to smoking, occupational exposure, or other illnesses. Endogenous lipoid pneumonia and non-specific interstitial pneumonitis has been seen prior to the development of PAP in a child. [26]

History

PAP was first described in 1958 [27] by the physicians Samuel Rosen, Benjamin Castleman, and Averill Liebow. [28] In their case series published in the New England Journal of Medicine on June 7 of that year, they described 27 patients with pathologic evidence of periodic acid Schiff positive material filling the alveoli. This lipid rich material was subsequently recognized to be surfactant.[ citation needed ]

The reported treatment of PAP using therapeutic bronchoalveolar lavage was in 1960 by Dr. Jose Ramirez-Rivera at the Veterans' Administration Hospital in Baltimore, [29] who described repeated "segmental flooding" as a means of physically removing the accumulated alveolar material. [30]

Research

PAP is one of the rare lung diseases currently being studied by the Rare Lung Diseases Consortium. The consortium is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, of the National Center for Advancing Translational Sciences, and dedicated to developing new diagnostics and therapeutics for patients with rare lung diseases, through collaboration between the National Institutes of Health, patient organizations and clinical investigators.[ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Pulmonary alveolus</span> Hollow cavity found in the lungs

A pulmonary alveolus, also known as an air sac or air space, is one of millions of hollow, distensible cup-shaped cavities in the lungs where pulmonary gas exchange takes place. Oxygen is exchanged for carbon dioxide at the blood–air barrier between the alveolar air and the pulmonary capillary. Alveoli make up the functional tissue of the mammalian lungs known as the lung parenchyma, which takes up 90 percent of the total lung volume.

<span class="mw-page-title-main">Interstitial lung disease</span> Group of diseases

Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of respiratory diseases affecting the interstitium and space around the alveoli of the lungs. It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues. It may occur when an injury to the lungs triggers an abnormal healing response. Ordinarily, the body generates just the right amount of tissue to repair damage, but in interstitial lung disease, the repair process is disrupted, and the tissue around the air sacs (alveoli) becomes scarred and thickened. This makes it more difficult for oxygen to pass into the bloodstream. The disease presents itself with the following symptoms: shortness of breath, nonproductive coughing, fatigue, and weight loss, which tend to develop slowly, over several months. The average rate of survival for someone with this disease is between three and five years. The term ILD is used to distinguish these diseases from obstructive airways diseases.

<span class="mw-page-title-main">Granulocyte-macrophage colony-stimulating factor</span> Mammalian protein found in Homo sapiens

Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as colony-stimulating factor 2 (CSF2), is a monomeric glycoprotein secreted by macrophages, T cells, mast cells, natural killer cells, endothelial cells and fibroblasts that functions as a cytokine. The pharmaceutical analogs of naturally occurring GM-CSF are called sargramostim and molgramostim.

<span class="mw-page-title-main">Pulmonary surfactant</span> Complex of phospholipids and proteins

Pulmonary surfactant is a surface-active complex of phospholipids and proteins formed by type II alveolar cells. The proteins and lipids that make up the surfactant have both hydrophilic and hydrophobic regions. By adsorbing to the air-water interface of alveoli, with hydrophilic head groups in the water and the hydrophobic tails facing towards the air, the main lipid component of surfactant, dipalmitoylphosphatidylcholine (DPPC), reduces surface tension.

<span class="mw-page-title-main">Pulmonary hemorrhage</span> Medical condition

Pulmonary hemorrhage is an acute bleeding from the lung, from the upper respiratory tract and the trachea, and the pulmonary alveoli. When evident clinically, the condition is usually massive. The onset of pulmonary hemorrhage is characterized by a cough productive of blood (hemoptysis) and worsening of oxygenation leading to cyanosis. Treatment should be immediate and should include tracheal suction, oxygen, positive pressure ventilation, and correction of underlying abnormalities such as disorders of coagulation. A blood transfusion may be necessary.

<span class="mw-page-title-main">Pneumonitis</span> General inflammation of lung tissue

Pneumonitis describes general inflammation of lung tissue. Possible causative agents include radiation therapy of the chest, exposure to medications used during chemo-therapy, the inhalation of debris, aspiration, herbicides or fluorocarbons and some systemic diseases. If unresolved, continued inflammation can result in irreparable damage such as pulmonary fibrosis.

<span class="mw-page-title-main">Cryptogenic organizing pneumonia</span> Medical condition

Cryptogenic organizing pneumonia (COP), formerly known as bronchiolitis obliterans organizing pneumonia (BOOP), is an inflammation of the bronchioles (bronchiolitis) and surrounding tissue in the lungs. It is a form of idiopathic interstitial pneumonia.

Bronchoalveolar lavage (BAL), also known as bronchoalveolar washing, is a diagnostic method of the lower respiratory system in which a bronchoscope is passed through the mouth or nose into an appropriate airway in the lungs, with a measured amount of fluid introduced and then collected for examination. This method is typically performed to diagnose pathogenic infections of the lower respiratory airways, though it also has been shown to have utility in diagnosing interstitial lung disease. Bronchoalveolar lavage can be a more sensitive method of detection than nasal swabs in respiratory molecular diagnostics, as has been the case with SARS-CoV-2 where bronchoalveolar lavage samples detect copies of viral RNA after negative nasal swab testing.

<span class="mw-page-title-main">Lipid pneumonia</span> Lung inflammation caused by lipids in the bronchial tree

Lipoid pneumonia is a specific form of lung inflammation (pneumonia) that develops when lipids enter the bronchial tree. The disorder is sometimes called cholesterol pneumonia in cases where that lipid is a factor.

<span class="mw-page-title-main">Alveolar lung disease</span> Medical condition

Alveolar lung diseases, are a group of diseases that mainly affect the alveoli of the lungs.

<span class="mw-page-title-main">Granulocyte-macrophage colony-stimulating factor receptor</span> Protein-coding gene in humans

The granulocyte-macrophage colony-stimulating factor receptor, also known as CD116, is a receptor for granulocyte-macrophage colony-stimulating factor, which stimulates the production of white blood cells. In contrast to M-CSF and G-CSF which are lineage specific, GM-CSF and its receptor play a role in earlier stages of development. The receptor is primarily located on neutrophils, eosinophils and monocytes/macrophages, it is also on CD34+ progenitor cells (myeloblasts) and precursors for erythroid and megakaryocytic lineages, but only in the beginning of their development.

<span class="mw-page-title-main">Desquamative interstitial pneumonia</span> Medical condition

Desquamative interstitial pneumonia (DIP) is a form of idiopathic interstitial pneumonia featuring elevated numbers of macrophages within the alveoli of the lung. The alveolar macrophages have a characteristic light brown pigmentation and accumulate in the alveolar lumen and septa regions of the lower lobes of the lungs. The typical effects of the macrophage accumulation are inflammation and later fibrosis of the lung tissue.

MonoMAC syndrome is a rare autosomal dominant syndrome associated with: monocytopenia, B and NK cell lymphopenia; mycobacterial, viral, fungal, and bacterial opportunistic infections; and virus infection-induced cancers. The disorder often progresses to the development of myelodysplasia, myeloid leukemias, and other types of cancer. MonoMAC is a life-threatening and precancerous disorder.

Tolerogenic therapy aims to induce immune tolerance where there is pathological or undesirable activation of the normal immune response. This can occur, for example, when an allogeneic transplantation patient develops an immune reaction to donor antigens, or when the body responds inappropriately to self antigens implicated in autoimmune diseases. It must provide absence of specific antibodies for exactly that antigenes.

Indium lung is a rare occupational lung disease caused by exposure to respirable indium in the form of indium tin oxide. It is classified as an interstitial lung disease.

<span class="mw-page-title-main">Pulmonary alveolar microlithiasis</span> Medical condition

Pulmonary alveolar microlithiasis (PAM) is a rare, inherited disorder of lung phosphate balance that is associated with small stone formation in the airspaces of the lung. Mutations in the gene SLC34A2 result in loss of a key sodium, phosphate co-transporter, known to be expressed in distal alveolar type II cells, as well as in the mammary gland, and to a lesser extent in intestine, kidney, skin, prostate and testes. As the disease progresses, the lung fields become progressively more dense (white) on the chest xray, and low oxygen level, lung inflammation and fibrosis, elevated pressures in the lung blood vessels, and respiratory failure ensue, usually in middle age. The clinical course of PAM can be highly variable, with some patients remaining asymptomatic for decades, and others progressing more rapidly. There is no effective treatment, and the mechanisms of stone formation, inflammation and scarring are not known.

GATA2 deficiency is a grouping of several disorders caused by common defect, namely, familial or sporadic inactivating mutations in one of the two parental GATA2 genes. Being the gene haploinsufficient, mutations that cause a reduction in the cellular levels of the gene's product, GATA2, are autosomal dominant. The GATA2 protein is a transcription factor critical for the embryonic development, maintenance, and functionality of blood-forming, lymphatic-forming, and other tissue-forming stem cells. In consequence of these mutations, cellular levels of GATA2 are deficient and individuals develop over time hematological, immunological, lymphatic, or other presentations that may begin as apparently benign abnormalities but commonly progress to severe organ failure, opportunistic infections, virus infection-induced cancers, the myelodysplastic syndrome, and/or leukemia. GATA2 deficiency is a life-threatening and precancerous condition.

Otilimab is a fully human antibody which has been developed by the biotechnology company MorphoSys. It can also be referred to as HuCAL antibody, HuCAL standing for Human Combinatorial Antibody Library and being a technology used to generate monoclonal antibodies. Otilimab is directed against the granulocyte-macrophage colony stimulating factor (GM-CSF), a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils.

<span class="mw-page-title-main">Lipid-laden alveolar macrophage</span> Pathological cells in lung

Lipid-laden alveolar macrophages, also known as pulmonary foam cells, are cells found in bronchoalveolar lavage (BAL) specimens that consist of macrophages containing deposits of lipids (fats). The lipid content of the macrophages can be demonstrated using a lipid targeting stain like Oil Red O or Nile red. Increased levels of lipid-laden alveolar macrophages are associated with various respiratory conditions, including chronic smoking, gastroesophageal reflux, lipoid pneumonia, fat embolism, pulmonary alveolar proteinosis and pulmonary aspiration. Lipid-laden alveolar macrophages have been reported in cases of vaping-associated pulmonary injury.

Whole lung lavage (WLL), also called lung washing, is a medical procedure in which the patient's lungs are washed with saline by filling and draining repeatedly. It is used to treat pulmonary alveolar proteinosis, in which excess lung surfactant proteins prevent the patient from breathing. Some sources consider it a variation of bronchoalveolar lavage.

References

  1. 1 2 Shah PL, Hansell D, Lawson PR, Reid KB, Morgan C (January 2000). "Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis". Thorax. 55 (1): 67–77. doi:10.1136/thorax.55.1.67. PMC   1745595 . PMID   10607805.
  2. 1 2 Kumar A, Abdelmalak B, Inoue Y, Culver DA (July 2018). "Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach". The Lancet. Respiratory Medicine. 6 (7): 554–565. doi:10.1016/s2213-2600(18)30043-2. PMID   29397349. S2CID   27932336.
  3. ↑ Oller AR, Kirkpatrick DT, Radovsky A, Bates HK (December 2008). "Inhalation carcinogenicity study with nickel metal powder in Wistar rats". Toxicology and Applied Pharmacology. 233 (2): 262–75. doi:10.1016/j.taap.2008.08.017. PMID   18822311.
  4. ↑ Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, et al. (June 1994). "Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology". Proceedings of the National Academy of Sciences of the United States of America. 91 (12): 5592–6. Bibcode:1994PNAS...91.5592S. doi: 10.1073/pnas.91.12.5592 . PMC   44042 . PMID   8202532.
  5. ↑ Uchida K, Beck DC, Yamamoto T, Berclaz PY, Abe S, Staudt MK, et al. (February 2007). "GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis". The New England Journal of Medicine. 356 (6): 567–79. doi: 10.1056/NEJMoa062505 . PMID   17287477.
  6. ↑ Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103–2110. doi:10.1182/blood-2016-09-687889. PMC   5391620 . PMID   28179280.
  7. ↑ Hirabayashi S, Wlodarski MW, Kozyra E, Niemeyer CM (August 2017). "Heterogeneity of GATA2-related myeloid neoplasms". International Journal of Hematology. 106 (2): 175–182. doi: 10.1007/s12185-017-2285-2 . PMID   28643018.
  8. ↑ “Pulmonary Alveolar Proteinosis.” NORD (National Organization for Rare Disorders), 16 Jan. 2020, rarediseases.org/rare-diseases/pulmonary-alveolar-proteinosis/.
  9. ↑ Whitsett JA, Wert SE, Weaver TE (2015). "Diseases of pulmonary surfactant homeostasis". Annual Review of Pathology. 10: 371–93. doi:10.1146/annurev-pathol-012513-104644. PMC   4316199 . PMID   25621661.
  10. ↑ Uchida K, Nakata K, Carey B, Chalk C, Suzuki T, Sakagami T, et al. (January 2014). "Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis". Journal of Immunological Methods. 402 (1–2): 57–70. doi:10.1016/j.jim.2013.11.011. PMC   7985885 . PMID   24275678.
  11. ↑ Holbert JM, Costello P, Li W, Hoffman RM, Rogers RM (May 2001). "CT features of pulmonary alveolar proteinosis". AJR. American Journal of Roentgenology. 176 (5): 1287–94. doi: 10.2214/ajr.176.5.1761287 . PMID   11312196.
  12. ↑ Das M, Salzman GA (February 2010). "Pulmonary alveolar proteinosis: an overview for internists and hospital physicians". Hospital Practice. 38 (1): 43–9. doi:10.3810/hp.2010.02.277. PMID   20469623. S2CID   21084414.
  13. 1 2 Mikami T, Yamamoto Y, Yokoyama M, Okayasu I (December 1997). "Pulmonary alveolar proteinosis: diagnosis using routinely processed smears of bronchoalveolar lavage fluid". Journal of Clinical Pathology. 50 (12): 981–4. doi:10.1136/jcp.50.12.981. PMC   500376 . PMID   9516877.
  14. 1 2 3 Maygarden SJ, Iacocca MV, Funkhouser WK, Novotny DB (June 2001). "Pulmonary alveolar proteinosis: a spectrum of cytologic, histochemical, and ultrastructural findings in bronchoalveolar lavage fluid". Diagnostic Cytopathology. 24 (6): 389–95. doi:10.1002/dc.1086. PMID   11391819. S2CID   1511222.
  15. ↑ Ceruti M, Rodi G, Stella GM, Adami A, Bolongaro A, Baritussio A, et al. (March 2007). "Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report". Orphanet Journal of Rare Diseases. 2: 14. doi: 10.1186/1750-1172-2-14 . PMC   1845139 . PMID   17386098.
  16. ↑ Menard KJ (April 2005). "Whole lung lavage in the treatment of pulmonary alveolar proteinosis". Journal of PeriAnesthesia Nursing. 20 (2): 114–26. doi:10.1016/j.jopan.2005.01.005. PMID   15806528.
  17. ↑ Griese M, Ripper J, Sibbersen A, Lohse P, Lohse P, Brasch F, et al. (August 2011). "Long-term follow-up and treatment of congenital alveolar proteinosis". BMC Pediatrics. 11 (1): 72. doi: 10.1186/1471-2431-11-72 . PMC   3175167 . PMID   21849033.
  18. 1 2 "Pulmonary Alveolar Proteinosis (PAP) Management and Treatment". Cleveland Clinic. Retrieved 2020-12-02.
  19. 1 2 "UpToDate". www.uptodate.com. Retrieved 2020-12-01.
  20. 1 2 3 "Pulmonary Alveolar Proteinosis". NORD (National Organization for Rare Disorders). Retrieved 2020-12-01.
  21. ↑ Michaud G, Reddy C, Ernst A (December 2009). "Whole-lung lavage for pulmonary alveolar proteinosis". Chest. 136 (6): 1678–1681. doi:10.1378/chest.09-2295. PMID   19995769.
  22. 1 2 Griese M (August 2017). "Pulmonary Alveolar Proteinosis: A Comprehensive Clinical Perspective". Pediatrics. 140 (2): e20170610. doi: 10.1542/peds.2017-0610 . PMID   28771412. S2CID   19689627.
  23. ↑ Huddleston CB, Bloch JB, Sweet SC, de la Morena M, Patterson GA, Mendeloff EN (September 2002). "Lung transplantation in children". Annals of Surgery. 236 (3): 270–6. doi:10.1097/00000658-200209000-00003. PMC   1422580 . PMID   12192313.
  24. ↑ Bonella, Francesco; Borie, Raphael (1 April 2022). "Targeted therapy for pulmonary alveolar proteinosis: the time is now". European Respiratory Journal. 59 (4). doi:10.1183/13993003.02971-2021. PMID   35450922. S2CID   248322846 . Retrieved 27 November 2022.
  25. ↑ Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, et al. (April 2008). "Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan". American Journal of Respiratory and Critical Care Medicine. 177 (7): 752–62. doi:10.1164/rccm.200708-1271OC. PMC   2720118 . PMID   18202348.
  26. ↑ Antoon JW, Hernandez ML, Roehrs PA, Noah TL, Leigh MW, Byerley JS (March 2016). "Endogenous lipoid pneumonia preceding diagnosis of pulmonary alveolar proteinosis". The Clinical Respiratory Journal. 10 (2): 246–9. doi:10.1111/crj.12197. PMID   25103284. S2CID   205037400.
  27. ↑ Seymour JF, Presneill JJ (July 2002). "Pulmonary alveolar proteinosis: progress in the first 44 years". American Journal of Respiratory and Critical Care Medicine. 166 (2): 215–35. doi:10.1164/rccm.2109105. PMID   12119235.
  28. ↑ Rosen SH, Castleman B, Liebow AA (June 1958). "Pulmonary alveolar proteinosis". The New England Journal of Medicine. 258 (23): 1123–42. doi:10.1056/NEJM195806052582301. PMID   13552931.
  29. ↑ Ramirez J, Nyka W, McLaughlin J (January 1963). "Pulmonary alveolar proteinosis. Diagnostic technics and observations". The New England Journal of Medicine. 268 (4): 165–71. doi:10.1056/NEJM196301242680401. PMID   13990655.
  30. ↑ Ramirez J, Schultz RB, Dutton RE (September 1963). "Pulmonary Alveolar Proteinosis: A New Technique and Rational for Treatment". Archives of Internal Medicine. 112 (3): 419–31. doi:10.1001/archinte.1963.03860030173021. PMID   14045290.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.